Scientific Reports (Mar 2023)

Full-length human dystrophin on human artificial chromosome compensates for mouse dystrophin deficiency in a Duchenne muscular dystrophy mouse model

  • Yosuke Hiramuki,
  • Satoshi Abe,
  • Narumi Uno,
  • Kanako Kazuki,
  • Shuta Takata,
  • Hitomaru Miyamoto,
  • Haruka Takayama,
  • Kayoko Morimoto,
  • Shoko Takehara,
  • Mitsuhiko Osaki,
  • Jun Tanihata,
  • Shin’ichi Takeda,
  • Kazuma Tomizuka,
  • Mitsuo Oshimura,
  • Yasuhiro Kazuki

DOI
https://doi.org/10.1038/s41598-023-31481-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Dystrophin maintains membrane integrity as a sarcolemmal protein. Dystrophin mutations lead to Duchenne muscular dystrophy, an X-linked recessive disorder. Since dystrophin is one of the largest genes consisting of 79 exons in the human genome, delivering a full-length dystrophin using virus vectors is challenging for gene therapy. Human artificial chromosome is a vector that can load megabase-sized genome without any interference from the host chromosome. Chimeric mice carrying a 2.4-Mb human dystrophin gene-loaded human artificial chromosome (DYS-HAC) was previously generated, and dystrophin expression from DYS-HAC was confirmed in skeletal muscles. Here we investigated whether human dystrophin expression from DYS-HAC rescues the muscle phenotypes seen in dystrophin-deficient mice. Human dystrophin was normally expressed in the sarcolemma of skeletal muscle and heart at expected molecular weights, and it ameliorated histological and functional alterations in dystrophin-deficient mice. These results indicate that the 2.4-Mb gene is enough for dystrophin to be correctly transcribed and translated, improving muscular dystrophy. Therefore, this technique using HAC gives insight into developing new treatments and novel humanized Duchenne muscular dystrophy mouse models with human dystrophin gene mutations.